NASDAQ:ANGN

Angion Biomedica (ANGN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$1.00
$10.00
52-Week Range
N/A
Volume
224,800 shs
Average Volume
86,718 shs
Market Capitalization
$30.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ANGN stock logo

About Angion Biomedica Stock (NASDAQ:ANGN)

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.

ANGN Stock News Headlines

8-K: Angion Biomedica Corp.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Lilly (LLY) Beats on Q3 Earnings & Sales, Lowers '22 View
Angion Biomedica Corp. (ANGN)
See More Headlines
Receive ANGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Angion Biomedica and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ANGN
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Net Income
$-38,810,000.00
Pretax Margin
-4,456.97%

Debt

Sales & Book Value

Annual Sales
$2.30 million
Book Value
$1.32 per share

Miscellaneous

Free Float
24,182,000
Market Cap
$30.11 million
Optionable
Not Optionable
Beta
0.60
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives


ANGN Stock Analysis - Frequently Asked Questions

How were Angion Biomedica's earnings last quarter?

Angion Biomedica Corp. (NASDAQ:ANGN) announced its quarterly earnings results on Friday, November, 12th. The company reported ($5.30) EPS for the quarter, topping analysts' consensus estimates of ($7.30) by $2.00. The company earned $1.46 million during the quarter, compared to the consensus estimate of $1.08 million.

When did Angion Biomedica's stock split?

Angion Biomedica's stock reverse split before market open on Friday, June 2nd 2023. The 1-10 reverse split was announced on Friday, June 2nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 2nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Angion Biomedica IPO?

Angion Biomedica (ANGN) raised $75 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Stifel served as the underwriters for the IPO and H.C. Wainwright & Co., LLC and Oppenheimer & Co. were co-managers.

This page (NASDAQ:ANGN) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners